Trump's “big, beautiful bill” and frenetic tariff activity have fueled a lobbying gusher in the opening months of his term.

Global healthcare stocks have not been this cheap in decades and fund inflows into the sector are picking up, yet the shares ...

Viatris Inc.'s proposed copy of Novo Nordisk A/S’ Wegovy doesn’t infringe a patent on using the once-weekly obesity drug ...

Novo Nordisk faces challenges in the competitive GLP-1 market, but its strong brand and R&D create opportunities for ...

Novo Nordisk A/S (NYSE:NVO) is a Danish pharmaceutical company that was one of the earliest movers in the weight loss drug market. The shares have lost 21% year-to-date due to multiple headwinds.

Hims & Hers Health, Inc. (HIMS) Faces Securities Class Actions After Novo Nordisk Cancels Partnership Over “Deceptive” Marketing of Wegovy– Hagens Berman ...

A U.S. appeals court has ruled that a Native Hawaiian man convicted of a hate crime against a white man must be re-sentenced, potentially adding years to his prison term.

Novo Nordisk, a global healthcare company focused on defeating serious chronic diseases, has announced the availability of Wegovy® (semaglutide 2.4mg) in Singapore.

Novo Nordisk's beaten-down valuation became too attractive to pass up, so I bought the stock earlier this year. Eli Lilly's GLP-1 drugs may have more potential, but Novo Nordisk is still likely to ...

Nevertheless, Novo Nordisk’s Ozempic and Rybelsus for diabetes and Wegovy for obesity are performing well, fueled by increasing demand.